UA91820C2 - Терапевтическое применение вариантов хемокинов - Google Patents

Терапевтическое применение вариантов хемокинов

Info

Publication number
UA91820C2
UA91820C2 UAA200604131A UAA200604131A UA91820C2 UA 91820 C2 UA91820 C2 UA 91820C2 UA A200604131 A UAA200604131 A UA A200604131A UA A200604131 A UAA200604131 A UA A200604131A UA 91820 C2 UA91820 C2 UA 91820C2
Authority
UA
Ukraine
Prior art keywords
seq
therapeutic uses
ccl2
autoimmune
inflammatory
Prior art date
Application number
UAA200604131A
Other languages
English (en)
Ukrainian (uk)
Inventor
Аманда Праудфут
Джеффри Шоу
Зоуи Джонсон
Original Assignee
Мерк Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Сероно С.А. filed Critical Мерк Сероно С.А.
Publication of UA91820C2 publication Critical patent/UA91820C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/24Immunology or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
UAA200604131A 2003-10-16 2004-10-18 Терапевтическое применение вариантов хемокинов UA91820C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03078308 2003-10-16

Publications (1)

Publication Number Publication Date
UA91820C2 true UA91820C2 (ru) 2010-09-10

Family

ID=34442986

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200604131A UA91820C2 (ru) 2003-10-16 2004-10-18 Терапевтическое применение вариантов хемокинов

Country Status (16)

Country Link
US (1) US7740833B2 (ru)
EP (1) EP1673103A1 (ru)
JP (1) JP2007510403A (ru)
KR (1) KR20070008510A (ru)
CN (1) CN1867352A (ru)
AR (1) AR046594A1 (ru)
AU (1) AU2004281552B2 (ru)
BR (1) BRPI0415290A (ru)
CA (1) CA2536082A1 (ru)
EA (1) EA009414B1 (ru)
IL (1) IL175020A0 (ru)
MX (1) MXPA06003695A (ru)
NO (1) NO20062109L (ru)
UA (1) UA91820C2 (ru)
WO (1) WO2005037305A1 (ru)
ZA (1) ZA200601900B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002101A (es) 2005-08-12 2008-04-19 Schering Corp Fusiones de la proteina-1 quimiotactica de monocito.
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
WO2007148317A1 (en) * 2006-06-21 2007-12-27 Compugen Ltd. Mcp-1 splice variants and methods of using same
CA2658719A1 (en) * 2006-07-24 2008-01-31 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising ccl2 and use of same for the treatment of inflammation
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
BRPI1008167A2 (pt) * 2009-01-30 2016-03-29 Protaffin Biotechnologie Ag mutantes de mcp-1 antagonizando glicosaminoglicano e método de usar os mesmos
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US9249204B2 (en) 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US8541564B2 (en) * 2011-06-01 2013-09-24 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US8796422B2 (en) * 2011-06-01 2014-08-05 Morehouse School Of Medicine Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
ES2664836T3 (es) * 2011-06-13 2018-04-23 Tla Targeted Immunotherapies Ab Tratamiento de esclerosis múltiple
US9726666B2 (en) 2011-06-13 2017-08-08 Tla Targeted Immunotherapies Ab Diagnosing and treating inflammatory diseases
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
WO2016126719A1 (en) * 2015-02-03 2016-08-11 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US10980739B2 (en) 2016-12-14 2021-04-20 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
KR102066149B1 (ko) * 2018-08-17 2020-01-14 고려대학교 산학협력단 Ccl2를 유효성분으로 포함하는 임신촉진용 조성물
CA3120619A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719331T4 (da) * 1993-09-14 2014-06-10 Imp Innovations Ltd Eotaxin: Eosinophil chemotaktisk cytokin
US5459128A (en) * 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
JP3837748B2 (ja) * 1997-01-17 2006-10-25 東亞合成株式会社 Vegf結合性ポリペプチド
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
RU2263118C2 (ru) * 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Комплексы антител с несколькими цитокинами
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
WO2003033677A2 (en) * 2001-10-19 2003-04-24 Zymogenetics, Inc. Dimerized growth factor and materials and methods for producing it
AU2003224761A1 (en) 2002-03-26 2003-10-13 Centocor, Inc. Mcp-1 mutant proteins, antibodies, compositions, methods and uses
RS89104A (en) * 2002-04-10 2006-12-15 Applied Research Systems Ars Holding N.V. Novel antagonists of mcp proteins
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors

Also Published As

Publication number Publication date
MXPA06003695A (es) 2006-06-20
EA200600782A1 (ru) 2006-08-25
BRPI0415290A (pt) 2006-12-19
JP2007510403A (ja) 2007-04-26
AU2004281552B2 (en) 2009-10-22
AU2004281552A1 (en) 2005-04-28
EA009414B1 (ru) 2007-12-28
EP1673103A1 (en) 2006-06-28
IL175020A0 (en) 2006-08-20
US20070280958A1 (en) 2007-12-06
WO2005037305A1 (en) 2005-04-28
CN1867352A (zh) 2006-11-22
AR046594A1 (es) 2005-12-14
KR20070008510A (ko) 2007-01-17
US7740833B2 (en) 2010-06-22
NO20062109L (no) 2006-05-11
ZA200601900B (en) 2007-07-25
CA2536082A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
MXPA05013564A (es) Proteinas de fusion.
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
AU2003228962A8 (en) Ferritin fusion proteins for use in vaccines and other applications
WO2005024044A3 (en) Method for the production of fusion proteins in transgenic mammal milk
HUP0004560A2 (hu) Törést gyógyító PTHrP analógok
GB0100551D0 (en) Protein
WO2006032923A3 (en) Inhibitors of protein kinase a anchoring
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2003051926A3 (en) Anti-cd7 immunotoxin as fusion protein
RU2001132140A (ru) Рекомбинантный рецептор коллагена на тромбоцитах гликопротеин VI и его применение в фармацевтике
NZ508816A (en) Bactericidal/permeability-increasing protein (BPI) deletion analogs
WO2002081507A3 (en) Interferon gamma polypeptide variants
WO2002004487A3 (de) Verfahren zur gewinnung und anwendung neuer humaner defensine als biologisch aktive eiweisstoffe zur behandlung von infektionen und anderen erkrankungen
EA200801077A1 (ru) Антагонисты взаимодействия pf4 и rantes
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
HUP0300787A2 (hu) Új interferon a sclerosis multiplex kezelésére
MX2022008748A (es) Administración oral de péptidos.
WO2004033705A3 (en) Viral interferon antagonists and uses therefor
WO2002036628A3 (en) New multimeric interferon beta polypeptides
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
SE9402332D0 (sv) Igf-1
WO2004011638A3 (en) Deoxyuridine 5' triphosphate nucleotidohydrolase polypeptides and structures
WO2001075041A3 (fr) Nouveau polypeptide, proteine humaine associee a l'epilepsie 11, et polynucleotide codant pour ce polypeptide